LIGAND PHARMACEUTICALS INCORPORATED: proceeds from issuing common stock

What this measure means

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Exact concept: us-gaap:ProceedsFromIssuanceOfCommonStock. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2009-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• LIGAND PHARMACEUTICALS INCORPORATED: total assets
• LIGAND PHARMACEUTICALS INCORPORATED: total liabilities
• LIGAND PHARMACEUTICALS INCORPORATED: stockholders equity
• LIGAND PHARMACEUTICALS INCORPORATED: cash and cash equivalents
• LIGAND PHARMACEUTICALS INCORPORATED: net income or loss
• LIGAND PHARMACEUTICALS INCORPORATED: operating cash flow
• LIGAND PHARMACEUTICALS INCORPORATED: capital expenditure payments
• LIGAND PHARMACEUTICALS INCORPORATED: revenue
• LIGAND PHARMACEUTICALS INCORPORATED: contract revenue excluding tax
• LIGAND PHARMACEUTICALS INCORPORATED: financing cash flow
• LIGAND PHARMACEUTICALS INCORPORATED: investing cash flow
• LIGAND PHARMACEUTICALS INCORPORATED: retained earnings or deficit
• LIGAND PHARMACEUTICALS INCORPORATED: basic weighted-average shares
• LIGAND PHARMACEUTICALS INCORPORATED: diluted weighted-average shares
• LIGAND PHARMACEUTICALS INCORPORATED: basic earnings per share
• LIGAND PHARMACEUTICALS INCORPORATED: diluted earnings per share
• LIGAND PHARMACEUTICALS INCORPORATED: income tax expense or benefit
• LIGAND PHARMACEUTICALS INCORPORATED: net property, plant and equipment
• LIGAND PHARMACEUTICALS INCORPORATED: share-based compensation expense
• LIGAND PHARMACEUTICALS INCORPORATED: operating income or loss
• LIGAND PHARMACEUTICALS INCORPORATED: current assets
• LIGAND PHARMACEUTICALS INCORPORATED: interest expense
• LIGAND PHARMACEUTICALS INCORPORATED: current liabilities
• LIGAND PHARMACEUTICALS INCORPORATED: current accounts payable
• LIGAND PHARMACEUTICALS INCORPORATED: goodwill carrying amount
• LIGAND PHARMACEUTICALS INCORPORATED: net current accounts receivable
• LIGAND PHARMACEUTICALS INCORPORATED: common-stock repurchase payments
• LIGAND PHARMACEUTICALS INCORPORATED: net inventory
• LIGAND PHARMACEUTICALS INCORPORATED: research and development expense
• LIGAND PHARMACEUTICALS INCORPORATED: common shares outstanding
• LIGAND PHARMACEUTICALS INCORPORATED: cash including restricted cash
• LIGAND PHARMACEUTICALS INCORPORATED: additional paid-in capital
• LIGAND PHARMACEUTICALS INCORPORATED: accumulated other comprehensive income or loss
• LIGAND PHARMACEUTICALS INCORPORATED: total equity including noncontrolling interests
• LIGAND PHARMACEUTICALS INCORPORATED: operating lease right-of-use asset
• LIGAND PHARMACEUTICALS INCORPORATED: operating lease liability
• LIGAND PHARMACEUTICALS INCORPORATED: gross property, plant and equipment
• LIGAND PHARMACEUTICALS INCORPORATED: accumulated depreciation on property, plant and equipment
• LIGAND PHARMACEUTICALS INCORPORATED: net intangible assets excluding goodwill
• LIGAND PHARMACEUTICALS INCORPORATED: other noncurrent assets
• LIGAND PHARMACEUTICALS INCORPORATED: other noncurrent liabilities
• LIGAND PHARMACEUTICALS INCORPORATED: accrued current liabilities
• LIGAND PHARMACEUTICALS INCORPORATED: current contract liabilities
• LIGAND PHARMACEUTICALS INCORPORATED: net deferred tax assets
• LIGAND PHARMACEUTICALS INCORPORATED: net deferred tax liabilities
• LIGAND PHARMACEUTICALS INCORPORATED: pre-tax income or loss from continuing operations
• LIGAND PHARMACEUTICALS INCORPORATED: profit or loss including noncontrolling interests
• LIGAND PHARMACEUTICALS INCORPORATED: comprehensive income or loss
• LIGAND PHARMACEUTICALS INCORPORATED: general and administrative expense
• LIGAND PHARMACEUTICALS INCORPORATED: depreciation expense
• LIGAND PHARMACEUTICALS INCORPORATED: depreciation, depletion and amortization
• LIGAND PHARMACEUTICALS INCORPORATED: amortization of intangible assets
• LIGAND PHARMACEUTICALS INCORPORATED: nonoperating interest expense
• LIGAND PHARMACEUTICALS INCORPORATED: other nonoperating income or expense
• LIGAND PHARMACEUTICALS INCORPORATED: nonoperating income or expense
• LIGAND PHARMACEUTICALS INCORPORATED: current income tax expense or benefit
• LIGAND PHARMACEUTICALS INCORPORATED: deferred income tax expense or benefit
• LIGAND PHARMACEUTICALS INCORPORATED: interest paid, net
• LIGAND PHARMACEUTICALS INCORPORATED: operating lease payments
• LIGAND PHARMACEUTICALS INCORPORATED: change in accounts receivable
• LIGAND PHARMACEUTICALS INCORPORATED: change in inventories

Inspect the source

Entity

LIGAND PHARMACEUTICALS INCORPORATED / CIK 0000886163

Captured

2026-09-20T05:02:56.440Z

SEC response SHA-256

26b9f549d8d5fedfcc22ffc2cb401b4aa39a0521a9ac5eadb8cab555ea7bf744

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000886163.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))